Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #NACD--Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree

Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Aptima--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) approved its Aptima CMV Quant assay to quantify the viral load of cytomegalovirus (CMV) in patients who have had solid organ or stem cell transplants. The test is the first to be introduced in the U.S. by Hologic for post-transplant pathogen detection and monitoring on Hologic's fully automated Panther® system, and joins the existing portfolio of diagnostic and vira

Hologic Announces FDA Approval of Aptima® CMV Quant Assay for Human Cytomegalovirus

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #bofaconference--Hologic to Webcast Presentation at Upcoming Investor Conference

Hologic to Webcast Presentation at Upcoming Investor Conference

Hologic Inc (NASDAQ: HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion. Lower sales of COVID-19 assays primarily drove a fall in sales.

Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue

Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.

Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up

Steve MacMillan, the CEO of medical technology company Hologic, warned that the global semiconductor chip shortage “impacts women's health.”

Chip shortage ‘impacts women's health': Hologic CEO

Hologic, Inc. (NASDAQ:HOLX ) Q2 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Steve MacMillan - Chairman, President and Chief Executive Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Puneet Souda - SVB Securities Tejas Savant - Morgan Stanley Casey Woodring - JPMorgan Derik de Bruin - Bank of America Ryan Zimmerman - BTIG Operator Good afternoon and welcome to the Hologic 2Q ‘22 Earnings Conference Call. My name is Lauren and I am your operator for today's call.

Hologic, Inc. (HOLX) CEO Steve MacMillan on Q2 2022 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 33.55% and 12.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q2 Earnings and Revenues Surpass Estimates

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #HOLX--Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal second quarter ended March 26, 2022. “In our second quarter of fiscal 2022, Hologic posted strong financial results that significantly exceeded our guidance on both the top and bottom lines,” said Steve MacMillan, the Company's chairman, president and chief executive officer. “We continued to generate robust profitability and cash flows in the quarter and our balance

Hologic Announces Financial Results for Second Quarter of Fiscal 2022

Hologic (HOLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Hologic (HOLX) This Earnings Season?

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #ASCO--ASCO Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy

American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Hologic (HOLX) Crossed Above the 20-Day Moving Average: What That Means for Investors

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic to Announce Financial Results for the Second Quarter of Fiscal 2022 on Wednesday, April 27, 2022

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2022 on Wednesday, April 27, 2022

AIX-EN-PROVENCE, France--(BUSINESS WIRE)-- #AixenProvence--Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women's health, opened its new Innovation Center today in Aix-en-Provence, France. This announcement follows Hologic's 2019 acquisition of Aix-en-Provence-based SuperSonic Imagine and further demonstrates Hologic's commitment to the EMEA region. The new commercial office, training and research and development facility will support Hologic's ultrasound,

Hologic Opens New Innovation Center in France

Is Hologic (HOLX) a great pick from the value investor's perspective right now? Read on to know more.

Can Value Investors Select Hologic (HOLX) Stock Now?

Automatic Data Processing

Bath and Body Works

CVS Health

Parker-Hannifin

Ralph Lauren

Tapestry

The number of companies raising guidance in 2022 has been slower than usual. Here are seven S&P 500 stocks that have upped guidance.

7 S&P 500 Stocks That Have Raised Their Guidance in 2022

INDIAN WELLS, Calif.--(BUSINESS WIRE)-- #HOLX--Hologic WTA Tour Swings into Action Ahead of BNP Paribas Open

Hologic WTA Tour Swings into Action Ahead of BNP Paribas Open

ST. PETERSBURG, Fla.--(BUSINESS WIRE)-- #HOLX--Hologic Partners With the WTA Tour in Landmark Title Sponsorship

Hologic Partners With the WTA Tour in Landmark Title Sponsorship

While COVID-19 has driven recent quarterly beats, the Street seems to be overlooking the better long-term positioning of Hologic's diagnostics business post-COVID-19. The pandemic greatly accelerated Hologic's diagnostics system placements and the large majority of COVID-19 customers are using the Panther system for other tests.

Hologic's Underperformance Makes This A Name Worth Further Consideration

The stock price of Hologic (NASDAQ: HOLX) increased by 1.66% in the most recent trading session. This is why it happened.

Hologic (HOLX) Stock: Why The Price Increased

Impressive performance by Hologic's (HOLX) Breast Imaging and Interventional Breast Solutions drove Q1 revenues.

Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Down

Hologic Inc  HOLX reported Q1 FY22 sales of $1.47 billion, beating the consensus of $1.18 billion and the company's expectations of $1.1 billion - $1.15 billion. Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

Hologic Q1 FY22 Sales Decline 9% On Lower COVID-19 Assay Sales; Issues Upbeat FY22 Outlook

Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q1 2022 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of 80.83% and 31.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q1 Earnings and Revenues Surpass Estimates

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #HOLX--Hologic Announces Financial Results for First Quarter of Fiscal 2022

News for Hologic Stock (HOLX)